{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=51",
    "query": {
      "condition": "Healthy Volunteers.",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 7030,
    "total_pages": 703,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=52&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=50&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:38:55.642Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04693247",
      "title": "Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Refractive Errors",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "EQ103",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EyeQue Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-10-28",
      "completion_date": "2023-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Newark, California",
      "locations": [
        {
          "city": "Newark",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693247"
    },
    {
      "nct_id": "NCT04766138",
      "title": "Trial to Evaluate Fecobionics in Healthy Subjects and Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Normal Subjects",
        "Fecal Incontinence"
      ],
      "interventions": [
        {
          "name": "Fecobionics",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The California Medical Innovations Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 35,
      "start_date": "2021-01-01",
      "completion_date": "2023-03-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766138"
    },
    {
      "nct_id": "NCT07543276",
      "title": "Pharmacokinetic (PK) Evaluation of Nalmefene Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Overdose"
      ],
      "interventions": [
        {
          "name": "Nalmefene + 0.94% MgCl2",
          "type": "DRUG"
        },
        {
          "name": "Nalmefene Hydrochloride Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Knoa Pharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2026-02-06",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07543276"
    },
    {
      "nct_id": "NCT00302458",
      "title": "A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "OROS-Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Immediate Release Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 44,
      "start_date": "2006-01",
      "completion_date": "2007-06",
      "has_results": true,
      "last_update_posted_date": "2016-02-29",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00302458"
    },
    {
      "nct_id": "NCT02059148",
      "title": "A Study of LY2835219 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LY2835219",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-02",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059148"
    },
    {
      "nct_id": "NCT02508740",
      "title": "Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "bevenopran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Years to 18 Years"
      },
      "enrollment_count": 31,
      "start_date": "2013-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-07-27",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 2,
      "location_summary": "Lakewood, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508740"
    },
    {
      "nct_id": "NCT02293148",
      "title": "Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "GSK1278863 75 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK1278863 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching GSK1278863",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2014-11-17",
      "completion_date": "2015-03-10",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293148"
    },
    {
      "nct_id": "NCT06740825",
      "title": "Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Rufinamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2024-10-29",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06740825"
    },
    {
      "nct_id": "NCT04591717",
      "title": "COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "hAd5-S-Fusion+N-ETSD vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-10-19",
      "completion_date": "2023-01-18",
      "has_results": false,
      "last_update_posted_date": "2023-02-28",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 2,
      "location_summary": "El Segundo, California • Newport Beach, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04591717"
    },
    {
      "nct_id": "NCT06477926",
      "title": "A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-668 IR",
          "type": "DRUG"
        },
        {
          "name": "ABBV-668 ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2024-07-09",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-11-19T07:38:55.642Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06477926"
    }
  ]
}